undamentalytics Newsletter
Sign in

Keros Therapeutics, Inc. revenue

Keros Therapeutics, Inc.'s revenue was $244m in fiscal 2025, up 6769.4% on the year before. Since fiscal 2019 ($10.0m) it has grown at a compound 70.3% a year. Over the last twelve months it was $14.9m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1002000424415
Growth on the year before—−100.0%—−100.0%—+>999%+>999%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Licenses $205M ▲ 6745.2%
License Revenue $205M —
Other services $38.7M ▲ 6937.5%
Services $38.5M —

These categories overlap or exclude eliminations, so shares aren't shown.

From Keros Therapeutics, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Keros Therapeutics, Inc. $14.9m -93.6% —
Alector, Inc. $13.9m -82.9% -48.6%
Lineage Cell Therapeutics, Inc. $13.1m 19.9% 7.5%
Proqr Therapeutics N.V. $18.0m -12.1% —
Cytomx Therapeutics, Inc. $18.3m -87.0% -38.7%
Celularity Inc $18.7m -58.1% 7.2%

Compare with peers

Head to head: ALEC vs KROSKROS vs LCTXKROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Keros Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Keros Therapeutics, Inc.